Discovering The Potential Drug Target Or Biomarker DIMT1 in Cancer

Target Name: DIMT1

NCBI ID: G27292

DIMT1

Discovering The Potential Drug Target Or Biomarker DIMT1 in Cancer

Dimethylation is a critical epigenetic process that plays a crucial role in cellular development, tissue homeostasis, and disease. One of the key enzymes involved in dimethylation is DIMT1 (M2(6)A dimethylase), an enzyme that has been identified as a potential drug target or biomarker for several diseases. In this article, we will discuss the structure and function of DIMT1, its potential drug target status, and its potential clinical applications.

Structure and Function

DIMT1 is a 21 kDa protein that is expressed in various tissues and cells, including brain, heart, liver, and pancreas. It is a member of the M2 group of DNA methyltransferases, which are involved in the transfer of methyl groups from the DNA to the N6 position on a specific G nitrogen base. DIMT1 is characterized by its unique catalytic mechanism, which involves the transfer of a methyl group from the substrate DNA to the enzyme's Active Site, followed by a subsequent transfer of a phosphate group to the substrate.

In addition to its catalytic mechanism, DIMT1 has several unique features that make it an attractive drug target or biomarker. Firstly, DIMT1 is a highly validated enzyme, with multiple independent studies demonstrating its functional role in various cellular processes. Secondly, DIMT1 has a well -characterized substrate specificity, with a specificity for 5-methylcytosine (5-MC) and 6-methylcytosine (6-MC) residues in DNA. This specificity makes DIMT1 a potential biomarker for diseases associated with DNA methylation disorders.

Potential Drug Target Status

DIMT1's unique catalytic mechanism and specificity make it an attractive target for drug development. Several studies have demonstrated that inhibition of DIMT1 has potential therapeutic benefits for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, several studies have shown that inhibition of DIMT1 has potential therapeutic benefits for cancer, including a reduction in the growth of cancer cells and a decrease in the formation of new blood vessels that feed those cells. This is because DIMT1 is involved in the Regulation of cell cycle progression, and inhibition of DIMT1 has been shown to disrupt the G1-S transition that occurs at the end of the cell cycle.

In addition to its potential therapeutic benefits, DIMT1 is also a potential biomarker for cancer, as its expression has been shown to be elevated in various types of cancer. This makes DIMT1 a promising target for cancer diagnostics and therapies.

Potential Clinical Applications

DIMT1's unique catalytic mechanism and specificity make it an attractive target for drug development, and several studies have shown that inhibition of DIMT1 has potential therapeutic benefits for a variety of diseases. In addition to its potential therapeutic benefits, DIMT1 is also a potential biomarker for cancer , making it an attractive target for cancer diagnostics and therapies.

In cancer, DIMT1 has been shown to play a critical role in the regulation of cell cycle progression and the development of cancer. Several studies have shown that inhibition of DIMT1 has potential therapeutic benefits for cancer, including a reduction in the growth of cancer cells and a decrease in the formation of new blood vessels that feed those cells.

In addition to its potential therapeutic benefits, DIMT1 is also a potential biomarker for cancer, as its expression has been shown to be elevated in various types of cancer. This makes DIMT1 a promising target for cancer diagnostics and therapies.

Conclusion

In conclusion, DIMT1 is a unique and promising enzyme that has been identified as a potential drug target or biomarker for several diseases. Its unique catalytic mechanism and specificity make it an attractive target for drug development, and its potential therapeutic benefits for cancer make it an attractive target for cancer diagnostics and therapies. Further research is needed to fully understand the role of DIMT1 in

Protein Name: DIM1 RRNA Methyltransferase And Ribosome Maturation Factor

Functions: Specifically dimethylates two adjacent adenosines in the loop of a conserved hairpin near the 3'-end of 18S rRNA in the 40S particle (PubMed:25851604). Involved in the pre-rRNA processing steps leading to small-subunit rRNA production independently of its RNA-modifying catalytic activity (PubMed:25851604). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797)

The "DIMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets